In conclusion, these results demonstrate an important role for miR-26a and CDK5 together in the survival and growth of DLBCL cells, suggesting the existence of potential novel therapeutic targets for the treatment of DLBCL. The gene discussed is CDK5; the disease is diffuse large B-cell lymphoma.